FDA will be getting feedback from advisors next month on plans for a more data-driven model approach to guiding and expediting the quality aspects of generic drug reviews.
FDA's Pharmaceutical Science and Clinical Pharmacology Committee will meet Sept. 20 on the agency's plans to liberate a quality review process that has become mired in text
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?